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I read with interest the article from Chytra and colleagues, who investigated the effectiveness and safety of continuous infusion (CI) of meropenem compared with intermittent infusion (II) in a large cohort (*n*= 240) of critically ill patients \[[@B1]\]. They found that although clinical cure at the end of therapy was similar between the two strategies, microbiological success was higher in the CI group and was independently associated with continuous drug administration. CI was also associated with a shorter ICU stay, as well as shorter duration of therapy and a lower total dose of meropenem. This paper highlights the potential benefits of CI of β-lactams compared with standard administration in critically ill patients, which has already been suggested in previous retrospective studies \[[@B2]\]. Nevertheless, some points need to be discussed.

First, the doses of meropenem used by Chytra and colleagues could be largely criticized. The authors have already underlined how the CI strategy received a lower daily regimen than the bolus strategy (4 g/day vs. 6 g/day) and the use of such an approach showed only clinical equivalence with but not superiority to II in clinical trials \[[@B3]\]. More importantly, the II group was treated with higher than recommended daily regimens (2 g every 8 hours rather than 1 g every 8 hours). In severe sepsis and septic shock, a 1 g loading dose of meropenem resulted in optimal serum concentrations to treat pathogen with a minimal inhibitory concentration (MIC) of 2 μg/ml in 75% of patients, while it provided adequate drug levels for lower MICs in all patients \[[@B4]\]. The same results were shown for both loading and steady-state doses when serum and subcutaneous drug levels were measured \[[@B5]\]. Calculating the doses of meropenem on population pharmacokinetic models from patients without critically illness may thus under estimate antibiotic concentrations measured in real populations and result in unnecessarily high drug regimens. Future research should therefore consider standard drug regimens (1 g every 8 hours) as a valuable control for CI strategies in septic patients.

Second, the CI group received 4 g meropenem over 24 hours, aiming to reach 100% of the time that drug concentrations would be above the MIC (T\>MIC) for most Gram-negative pathogens. Nevertheless, carbapenems need only 40% T\>MIC to have bactericidal effects, because of the significant post-antibiotic effect and enhanced leucocyte activity shown in *in vitro*models \[[@B6]\]. As such, prolonging the infusion of meropenem over 3 hours between two administrations would be sufficient to maximize its antibacterial activity \[[@B3]\]. Clearly, further clinical investigations are needed to better identify the optimal T\>MIC to use when CI of β-lactams is given during life-threatening infections.

Third, because the median MIC of the pathogens was approximately 0.125 μg/ml, it is difficult to understand how CI could result in higher clinical cure and bacteriological response rates when compared with II. In one study, CI of cefepime resulted in similar clinical outcome and bacterial eradication when compared with II in critically ill patients \[[@B7]\]; however, the effectiveness of drug concentrations at steady state was also similar between the two strategies because most of the isolated pathogens were highly susceptible to the study drug. On the contrary, CI of ceftazidime was associated with a greater clinical cure rate than II in patients with ventilator-associated pneumonia, particularly for those infections caused by organisms with MIC 8 μg/ml \[[@B2]\]. A CI strategy may evidently result in better clinical outcome only when treating less susceptible strains, in which II is unable to achieve adequate T\>MIC, and would not necessarily be more advantageous for all critically ill patients.
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We thank Dr Taccone for his interest in our article \[[@B1]\] and for his remarks. In general, we agree with most of them. We actually tried to address similar comments in the discussion of our article. Nevertheless, we would like to add a few remarks and clarifications.

First, when we designed and started the study (2007), the dose of meropenem (2 g every 8 hours) for intermittent administration was calculated according to the suggestion for achievement of the antibiotic\'s optimal probability of target attainment and cumulative fraction of response in critically ill patients with serious infections \[[@B8],[@B9]\]. In view of the later published results from Taccone and colleagues \[[@B4]\] and owing to the low MIC of pathogens in our study, however, we retrospectively find the dose used (2 g every 8 hours) unnecessarily high.

Second, although in carbapenems the recommended minimum percentage of the dosing interval for T\>MIC is only 40%, in patients with serious bacterial infections the achievement of 100% T\>MIC displayed a significantly greater clinical cure (82% vs. 33%, *P*= 0.002) and bacteriological eradication (97% vs. 44%, *P*\< 0.001) \[[@B10],[@B11]\]. Maintaining antibiotic concentrations above the MIC for 100% of the dosing interval was thus used in our study.

Third, we agree with the statement that the efficacy of CI of β-lactams should be investigated in a population suffering from infections caused by less susceptible strains with elevated MICs (which we also pointed out in the conclusion to our article \[[@B1]\]).

To conclude, we concur with the comments of Dr Taccone and we originally strove to elucidate them in the discussion of our article \[[@B1]\]. Bearing in mind these new facts and information, we would respect them if designing the study in the present day.
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